Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

Sylvia Ménard; A. Balsari; E. Tagliabue; T. Camerini; P. Casalini; R. Bufalino; F. Castiglioni; M. L. Carcangiu; A. Gloghini; S. Scalone; P. Querzoli; M. Lunardi; A. Molino; M. Mandarà; M. Mottolese; F. Marandino; M. Venturini; C. Bighin; G. Cancello; E. Montagna; F. Perrone; A. De Matteis; A. Sapino; M. Donadio; N. Battelli; A. Santinelli; L. Pavesi; A. Lanza; F. A. Zito; A. Labriola; R. A. Aiello; M. Caruso; F. Zanconati; G. Mustacchi; M. Barbareschi; M. Frisinghelli; R. Russo; G. Carrillo

doi:10.1093/annonc/mdn369

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

Sylvia Ménard, A. Balsari, E. Tagliabue, T. Camerini, P. Casalini, R. Bufalino, F. Castiglioni, M. L. Carcangiu, A. Gloghini, S. Scalone, P. Querzoli, M. Lunardi, A. Molino, M. Mandarà, M. Mottolese, F. Marandino, M. Venturini, C. Bighin, G. Cancello, E. MontagnaF. Perrone, A. De Matteis, A. Sapino, M. Donadio, N. Battelli, A. Santinelli, L. Pavesi, A. Lanza, F. A. Zito, A. Labriola, R. A. Aiello, M. Caruso, F. Zanconati, G. Mustacchi, M. Barbareschi, M. Frisinghelli, R. Russo, G. Carrillo

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.

Original language	English
Pages (from-to)	1706-1712
Number of pages	7
Journal	Annals of Oncology
Volume	19
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdn369
Publication status	Published - 2008

Keywords

HeceptTest
HER2
Prognosis
Therapy

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1093/annonc/mdn369

Fingerprint Dive into the research topics of 'Biology, prognosis and response to therapy of breast carcinomas according to HER2 score'. Together they form a unique fingerprint.

Cite this

Ménard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M. L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandarà, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., ... Carrillo, G. (2008). Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Annals of Oncology, 19(10), 1706-1712. https://doi.org/10.1093/annonc/mdn369

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. / Ménard, Sylvia; Balsari, A.; Tagliabue, E.; Camerini, T.; Casalini, P.; Bufalino, R.; Castiglioni, F.; Carcangiu, M. L.; Gloghini, A.; Scalone, S.; Querzoli, P.; Lunardi, M.; Molino, A.; Mandarà, M.; Mottolese, M.; Marandino, F.; Venturini, M.; Bighin, C.; Cancello, G.; Montagna, E.; Perrone, F.; De Matteis, A.; Sapino, A.; Donadio, M.; Battelli, N.; Santinelli, A.; Pavesi, L.; Lanza, A.; Zito, F. A.; Labriola, A.; Aiello, R. A.; Caruso, M.; Zanconati, F.; Mustacchi, G.; Barbareschi, M.; Frisinghelli, M.; Russo, R.; Carrillo, G.

In: Annals of Oncology, Vol. 19, No. 10, 2008, p. 1706-1712.

Research output: Contribution to journal › Article › peer-review

Ménard, S, Balsari, A, Tagliabue, E, Camerini, T, Casalini, P, Bufalino, R, Castiglioni, F, Carcangiu, ML, Gloghini, A , Scalone, S, Querzoli, P, Lunardi, M, Molino, A, Mandarà, M, Mottolese, M, Marandino, F, Venturini, M, Bighin, C , Cancello, G , Montagna, E , Perrone, F, De Matteis, A, Sapino, A, Donadio, M, Battelli, N, Santinelli, A, Pavesi, L, Lanza, A, Zito, FA, Labriola, A, Aiello, RA, Caruso, M, Zanconati, F, Mustacchi, G, Barbareschi, M, Frisinghelli, M, Russo, R & Carrillo, G 2008, 'Biology, prognosis and response to therapy of breast carcinomas according to HER2 score', Annals of Oncology, vol. 19, no. 10, pp. 1706-1712. https://doi.org/10.1093/annonc/mdn369

Ménard, Sylvia ; Balsari, A. ; Tagliabue, E. ; Camerini, T. ; Casalini, P. ; Bufalino, R. ; Castiglioni, F. ; Carcangiu, M. L. ; Gloghini, A. ; Scalone, S. ; Querzoli, P. ; Lunardi, M. ; Molino, A. ; Mandarà, M. ; Mottolese, M. ; Marandino, F. ; Venturini, M. ; Bighin, C. ; Cancello, G. ; Montagna, E. ; Perrone, F. ; De Matteis, A. ; Sapino, A. ; Donadio, M. ; Battelli, N. ; Santinelli, A. ; Pavesi, L. ; Lanza, A. ; Zito, F. A. ; Labriola, A. ; Aiello, R. A. ; Caruso, M. ; Zanconati, F. ; Mustacchi, G. ; Barbareschi, M. ; Frisinghelli, M. ; Russo, R. ; Carrillo, G. / Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. In: Annals of Oncology. 2008 ; Vol. 19, No. 10. pp. 1706-1712.

@article{dac15c4fc45c46368c453ce9aacac4e6,

title = "Biology, prognosis and response to therapy of breast carcinomas according to HER2 score",

abstract = "Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.",

keywords = "HeceptTest, HER2, Prognosis, Therapy",

author = "Sylvia M{\'e}nard and A. Balsari and E. Tagliabue and T. Camerini and P. Casalini and R. Bufalino and F. Castiglioni and Carcangiu, {M. L.} and A. Gloghini and S. Scalone and P. Querzoli and M. Lunardi and A. Molino and M. Mandar{\`a} and M. Mottolese and F. Marandino and M. Venturini and C. Bighin and G. Cancello and E. Montagna and F. Perrone and {De Matteis}, A. and A. Sapino and M. Donadio and N. Battelli and A. Santinelli and L. Pavesi and A. Lanza and Zito, {F. A.} and A. Labriola and Aiello, {R. A.} and M. Caruso and F. Zanconati and G. Mustacchi and M. Barbareschi and M. Frisinghelli and R. Russo and G. Carrillo",

year = "2008",

doi = "10.1093/annonc/mdn369",

language = "English",

volume = "19",

pages = "1706--1712",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "10",

}

TY - JOUR

T1 - Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

AU - Ménard, Sylvia

AU - Balsari, A.

AU - Tagliabue, E.

AU - Camerini, T.

AU - Casalini, P.

AU - Bufalino, R.

AU - Castiglioni, F.

AU - Carcangiu, M. L.

AU - Gloghini, A.

AU - Scalone, S.

AU - Querzoli, P.

AU - Lunardi, M.

AU - Molino, A.

AU - Mandarà, M.

AU - Mottolese, M.

AU - Marandino, F.

AU - Venturini, M.

AU - Bighin, C.

AU - Cancello, G.

AU - Montagna, E.

AU - Perrone, F.

AU - De Matteis, A.

AU - Sapino, A.

AU - Donadio, M.

AU - Battelli, N.

AU - Santinelli, A.

AU - Pavesi, L.

AU - Lanza, A.

AU - Zito, F. A.

AU - Labriola, A.

AU - Aiello, R. A.

AU - Caruso, M.

AU - Zanconati, F.

AU - Mustacchi, G.

AU - Barbareschi, M.

AU - Frisinghelli, M.

AU - Russo, R.

AU - Carrillo, G.

PY - 2008

Y1 - 2008

N2 - Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.

AB - Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.

KW - HeceptTest

KW - HER2

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=53049084124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049084124&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn369

DO - 10.1093/annonc/mdn369

M3 - Article

C2 - 18544559

AN - SCOPUS:53049084124

VL - 19

SP - 1706

EP - 1712

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -